| A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer (NCT07757230) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2026-09-01 |
| SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors (NCT07646626) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2026-07-17 |
| A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants (NCT07606976) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2026-06-01 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion (NCT07487545) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2026-03-31 |
| The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. (NCT07445308) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2026-03-12 |
| A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers (NCT07233850) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-11-01 |
| A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients (NCT07171606) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-10-24 |
| Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects (NCT07058779) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-08-04 |
| SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (NCT07022002) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-07-30 |
| A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors (NCT07038005) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-07-30 |
| A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors (NCT07032298) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-07-18 |
| Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia (NCT07007936) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-07-01 |
| SSGJ-707 in Advanced Non-Small Cell Lung Cancer (NCT06980272) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-06-20 |
| Phase I Study of HBT-708 for Patients With Advanced Solid Tumors (NCT06993870) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-06-16 |
| A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors (NCT07016490) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-06-12 |
| A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males (NCT07025915) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-06-01 |
| A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors (NCT06944444) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-04-27 |
| A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects (NCT07024888) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-03-16 |
| Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (NCT06854276) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-03-01 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects (NCT07057726) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2024-10-09 |
| Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain (NCT07008703) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2024-03-27 |
| Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia (NCT06629376) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2023-11-20 |
| Phase II Dose-Finding of Oral SSS17 for Anemia in Non-Dialysis CKD (NCT07014631) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2023-03-01 |
| A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease (NCT05193201) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2022-01-16 |
| A Phase 1 Study of SSS17 in Healthy Subjects. (NCT04893187) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2021-07-26 |
| Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure (NCT05211167) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2021-07-01 |
| A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet (NCT04728984) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2020-09-07 |
| A Study of SSS17 in Healthy Subjects (NCT04317833) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2020-05-01 |
| A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers (NCT04047394) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2019-10-22 |
| Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis (NCT03950687) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2019-06-24 |
| The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment (NCT03673215) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2018-06-28 |
| A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. (NCT03388515) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2017-10-09 |